- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
MGC Pharmaceuticals shared with investors its financial report for its most recent quarter.
MGC Pharmaceuticals (ASX:MXC) shared with investors its financial report for its most recent quarter.
As quoted in the press release:
Key Operational Highlights:
- Multiple key milestones achieved for the Pharma operations including first materialprescription volumes issued, significant increase in patient numbers, and new revenue streams delivered
- Patients in Australia and the United Kingdom being prescribed MGC Pharma’s phytocannabinoid based investigational medicines commenced in earnest during August, passing the 200, 400 and 800 prescription milestones within weeks during September and October – total prescriptions issued to date reached 1,000 at the end of October
- Total cash receipts received for the September quarter of AU$413,000, with new Pharma revenue from recent sales of more than AU$400,000 to be received post quarter end
Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: “We have seen another period of excellent progress delivering on our ‘Seed to Medicine’ business strategy. We have achieved multiple milestones across our pharma business channels, the highlight being the continuing rapid growth of prescription numbers, doubling in just two weeks during September and continuing during October, which validates the quality and immediate patient demand for our phytocannabinoid based investigational medicinal products (IMP) and underpins our growth potential.
Click here to read the full press release.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â